Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer
- 1 November 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 82 (2), 113-123
- https://doi.org/10.1023/b:brea.0000003968.45511.3f
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot studyBreast Cancer Research and Treatment, 1999
- Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-upAnnals Of Oncology, 1999
- The relationship between prognostic and predictive factors in the management of breast cancerBreast Cancer Research and Treatment, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0)Cancer, 1997
- Ki-67, p53, Er-Receptors, Ploidy and S-Phase as Prognostic Factors in T1 Node Negative Breast CancerActa Oncologica, 1997
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piBritish Journal of Cancer, 1996
- Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancerBreast Cancer Research and Treatment, 1996
- Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor statusBritish Journal of Cancer, 1993
- Assessment of response to therapy in advanced breast cancerBritish Journal of Cancer, 1977